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Abstract Tumor necrosis factor-a (TNF~) is a potentially pow- 
erful anti-neoplastic agent; however, its therapeutic usefulness is 
limited by its cardiotoxic and negative inotropic effects. Accord- 
ingly, studies were undertaken to gain a better understanding of 
the mechanisms of TNFa-mediated cardiodepression. Single cell 
RT-PCR, [125I]TNF~ ligand binding and Western immunoblot- 
ting experiments demonstrated that rat cardiac cells predomi- 
nantly express type I TNFa receptors (TNFRI or p60). TNFa 
inhibited cardiac L-type Ca 2+ channel current (/ca) and contrac- 
tile Ca 2÷ transients. Thus, it is possible that the negative inotropic 
effects of TNF~ are the result of TNFRI-mediated blockade of 
cardiac excitation-contraction coupling. 
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1. Introduction 
The cytokine, tumor necrosis factor-~ (TNF~), is responsible 
for many cardiotoxic and negative inotropic effects of septic 
shock, tissue transplant and HIV infection [1-3]. The cardio- 
toxic effects of TNF~ have limited its usefulness as a therapeu- 
tic agent in human cancer therapy and as an anti-viral agent [4]. 
Hypotension resulting from the depressant effect of TNF~ on 
the heart constitutes a major dose-limiting toxic effect of TNF~ 
observed in phase I clinical trials [4]. TNF~ levels in blood are 
elevated with congestive heart failure [5] and viral myocarditis 
[6] and may promote negative inotropy in those conditions. 
TNF~ levels are elevated in human serum during septic shock 
and are correlated with the characteristic hypotension (systolic 
blood pressure < 90 mmHg) of the disease as well as with diffuse 
tissue injury, multiple-system organ failure and death resulting 
from severe sepsis [7]. In animal model systems, TNF~ has a 
negative inotropic effect on cardiac tissue [8 11]. TNF~ blocks 
spontaneous contractions of cultured murine cardiomyocytes 
[12] and reduces the size of Ca 2÷ transients in adult feline car- 
diomyocytes [13]. The mechanism by which TNF~ exerts car- 
diodepressant effects is not known primarily because cardiac 
TNF~ receptors have not been characterized and the signal 
transduction cascade(s) responsible for the acute effects of 
TNF~ have not been elucidated. In this study, we have identi- 
fied the type 1 TNFc~ receptor (TNFRI,  p60) on adult rat 
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cardiac myocytes. Further, we provide evidence suggesting that 
TNF~, presumably acting via the TNFRI ,  exerts its negative 
inotropic effect on cardiac cells in part by inhibiting the L-type 
Ca 2+ channel of the cardiac cell surface membrane. 
2. Materials and methods 
2.1. Cell and microsome preparation 
Acutely dissociated adult rat ventricular myocytes were prepared 
from adult (200-350 g) Sprague-Dawley rat hearts by enzymatic disso- 
ciation as described previously [14]. The Tyrode's olution used for cell 
isolation contained (mM): NaC1 140, KCI 5.4, MgCI z 0.5, CaC12 1.0, 
HEPES 10, and NaH2PO4 0.25 (pH 7.3). The adult rat myocytes were 
'Ca 2+ tolerant' in that they did not supercontract in the presence of 
1 mM Ca z÷ and they were responsive to electrical field stimulation. For 
single cell RT-PCR, cells were plated on laminin-coated (50 pg/ml) glass 
coverslips and cultured 18 24 h in DMEM/F 12 medium supplemented 
with 10% fetal calf serum and antibiotics, as previously described [15]. 
Rat cardiac, skeletal and liver microsomal fractions were obtained by 
utilizing methods described previously for canine membranes [16]. Iso- 
lated membranes were used for the Western immunoblotting and 
[~25]TNFc~ ligand blotting experiments ( ee below). Protein concentra- 
tion was determined by the Lowry method [17]. 
2.2. Ca 2+ current (It,,) and Ca 2+ transient measurements 
Calcium currents (/co) were recorded from single cells patch-clamped 
in the whole-cell configuration as previously described [18-20]. The 
effects of TNFc~ on the Ca 2. transients and their comparison with the 
TNFc~ inhibition of the/ca, were examined in 13 cells electrically paced 
at 0.3 Hz for their responses to a level of recombinant murine TNFc~ 
(rmTNFc~; 18.000 U/ml; Genzyme, Cambridge, MA) and other condi- 
tions (e.g. 5 rain incubation) used in the L-channel work. Fluorescent 
measurements were performed as previously described [20]. For each 
of the 13 cells studied, 5 transients were analyzed immediately prior to 
TNFc~ addition and were compared to 5 transients exhibited by the cells 
4.5 5 min later. In these experiments, 10 mM BSA was present either 
as a control or as a TNFc~ diluent o prevent TNF~ from sticking to 
the chamber surfaces. 
2.3. Whole tissue and single cell RT-PCR 
Expression of the TNFRI gene in the rat heart was determined by 
both single cell RT-PCR and amplification of cDNA reverse tran- 
scribed from whole tissue mRNA. Total RNA from adult rat ventricu- 
lar tissue was isolated by acid/guanidinium thiocyanatelphenol/chloro- 
form extraction and quantified by ultraviolet absorption at 260 nm as 
described [15,21]. Aliquots of total RNA were electrophoresed on 1% 
agarose gels followed by ethidium bromide staining to rule out signifi- 
cant RNA degradation. Poly(A+) RNA was isolated by oligo(dT) cel- 
lulose chromatography (Promega). Purified transcript was reverse tran- 
scribed and subjected to PCR. Template cDNA was obtained from 
reverse transcription of the DNAse-treated (RNAse-free) poly(A)* 
RNA modified from [22,23]. Briefly, poly(A) ÷ RNA (5 pg) was reverse 
transcribed with random hexamer primers (100 pmol/reaction), dNTPs 
and avian myeloblastosis reverse transcriptase (AMVRT; Promega), 
extracted with phenol/chloroform, ethanol-precipitated at -70°C and 
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solabilized in water. PCR primers and annealing temperatures were 
sek'cted utilizing Oligo 4.0 Primer Analysis software (National Bio- 
sci~:nces Inc., Plymouth, MN)). Sense and antisense primers for TN FRI 
were 5'-GCTCCTGGCTCTGCTGAT-Y and 5'-AACATTTCTTTC- 
C(,ACAT-3', respectively. Primers for atrial natriuretic factor (ANF) 
we 'e 5'-AGCGGGGGCGGCACTTAG-3' (sense) and 5'-CTCCAAT- 
C( TGTCAATCC-3' (antisense). Primers were synthesized in the 
S[~SU Microchemical Core Facility, 
kliquots of the cDNA template were added to the primers (100 
pr ol), dNTP (200 ~M of each dATP, dCTP, dTTP, dGTP) with MgC1 z 
(2 riM) and Taq polymerase (1.25 U; Boehringer-Mannheim) and sub- 
jet :ed to 30 cycles of PCR (94°C (1 rain), 55°C (1 rain), 72°C (1 rain) 
fo owed by 3 rain at 72°C) using a programmable thermal cycler 
(P "C-100; MJ Research Inc., Watertown, MA). PCR products were 
et] anol precipitated, electrophoresed through a 2% agarose gel and 
vi~ aalized by ethidium bromide staining. Gels were photographed and 
th negative image of the gel was used for densitometry (Molecular 
D namics). The remainder of the PCR product was ethanol precipi- 
ta ,~d and digested with EcoRI and Xhol, isolated following electropho- 
re is from a 2% LMP Agarose gel and the 288 bp fragment was sub- 
el. ned into pBluescript (KS+) (Stratagene) and sequenced by the dide- 
o~ ¢ chain-termination method (Sequenase). 
2. .  Single cell RT-PCR 
Zxpression of TNFRI was determined by RT-PCR of RNA har- 
ve .ted from individual adult cardiac myocytes which were obtained by 
er ,ymatic dissociation of adult rat hearts as described [18 20]. Follow- 
in : overnight culture, cells were rinsed thoroughly to remove cell debris 
ar :1 incubated in Ca2+-free Tyrode's to minimize spontaneous myocyte 
cc ltractility which would interfere with seal formation and could ham- 
p~ • the extraction of cytoplasmic contents. Extraction of RNA from the 
is, lated cells was performed essentially as O'Dowd and co-workers 
dt ;cribed for chick ciliary ganglion cells [24]. Fire-polished, baked 
pi ~ettes with a 5 10 Mr2 resistance were filled with sterile Ca~-+-free 
T2 rode's olution. Individual cells were patch clamped in the whole cell 
c( afiguration [18--20]. After detection of whole cell currents, negative 
pJ ~'ssure (suction to 9 ml mark on 10 ml syringe for 2 5 min) was 
at plied to the pipette and a fraction of the cell's cytoplasmic contents 
w re aspirated into the patch pipette tip which was then broken against 
th : side of a 0.5 ml sterile microcentrifuge tube. Approximately 2/ll of 
tl~ : pipette's contents were expelled and rapidly mixed into 7.5 ~1 of 
ic-cold first strand cDNA synthesis mixture containing dNTPs 
(1 raM), random hexanucleotide primers (10 pM), RNAse (50 U) in 
2.~ x reverse transcription buffer, and DNAse I (10 U). First strand 
cl ,NA was synthesized by addition of 0.5 pl of AMVRT (20 U), fol- 
Io red by incubation at 42°C for 1 h. The reaction was terminated by 
in :ubating at 90°C ['or 10 min. cDNA from first strand synthesis reac- 
ti. n was subjected to PCR as described above t'or cardiac tissue eDNA 
a~ iplification utilizing rat TNFRl-specific primers. 
2. ;. Western blotting 
Cardiac, skeletal and liver microsomal proteins were separated by 
Sl )S-PAGE. and then electrotransferred to nitrocellulose membranes 
al d receptor protein expression was evaluated by Western blot analysis 
av described [25] with modifications. Protein samples were solubilized 
eiher in a reducing (0.125 M Tris-base pH 6.8, 280 mM SDS, 20% 
gl ,cerol, 2% fl-mercaptoethanol (fl-M E)) or in a non-reducing (without 
ft. VIE) SDS buffer. Samples (~40 pg) were electrophoresed onan 10% 
SI)S-polyacrylamide g l [26] using a mini-PROTEAN II (Bio-Rad, 
H :rcules, CA) apparatus with electrophoresis buffer (25 mM Tris-base, 
P2 mM glycine, 3 mM SDS). The transfers were performed at a 
c~ nstant 63 V for 16 h at 4°C in transfer buffer (12.5 mM Tris-base, 
9~ mM glycine. 20% methanol). The blots were blocked with 3% nonfat 
d y-milk in TBST (10 mM Tris-HC1 pH 8.0, 150 mM NaC1, 0.05% 
Y ¢een-20) solution for I h. Subsequently, the membranes were incu- 
b. ted overnight in TBST containing 3% nonfat dry-milk and the pri- 
rr try antibody (100 ng/ml monoclonal nti-human TNFRI IgG) (Gen- 
z,. me). Membranes were washed in TBST (2 x 15 rain) and incubated 
~th  biotinylated goat anti-mouse IgG (1 /,tg/ml) for 1 h. Following 
tL orough washing and incubation with an avidin-alkaline phosphatase 
c~ njugate ( l pg/ml), receptor protein was visualized with alkaline phos- 
p! atase substrates (p-nitro blue tetrazolium chloride (NBT; 30 mg/ml) 
a~ d 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt (BCIP; 15 
rr g/ml)). Immunoblots were analyzed by scanning laser densitometry 
(Molecular Dynamics, Sunnyvale, CA) and molecular weights of the 
immunoreactive microsomal proteins were calculated from the pre- 
stained protein standards by ImageQuant (Molecular Dynamics). 
2.6. [I'5I]TNF~ ligand blotting 
Cardiac membrane proteins were also electroblotted and processed 
for [125I]TNFc~ binding [27,28]. TNF~ was iodinated by the Chloram- 
ine-T method [27,28]. Identical results were obtained using either 
[~-SI]rhTNF~ (1500 Ci/mmol obtained from NEN/DuPont) or the 
[~-~I]rmTNF~ labeled by the Chloramine-T method. Membrane pro- 
teins were transferred to nitrocellulose and blocked with 3% non-fat 
dry-milk as described above using non-denaturing conditions for the 
initial electrophoretic separation of microsomal membrane protein. 
Ligand blots were performed as described in [28] with modifications. 
Briefly, membranes were incubated overnight in 500 pM [~-51]TNFc~ 
with or without 50 nM unlabelled TNF~ in TBST with 3% nonfat 
dry-milk. Blots were washed in TBST (4 x 15 min), air-dried and incu- 
bated on a storage phosphor screen (Molecular Dynamics) for 48 72 
h, scanned on a PhosphorImager (Molecular Dynamics) and analyzed 
using ImageQuant. Liver and skeletal microsomal membrane proteins 
were electroblotted and probed with ~2~I-TNF~ at the same time as the 
cardiac membranes and under identical conditions for comparison pur- 
poses. 
3. Results and discussion 
3.1. L -Type Ca :+ channel currents 
TNF~ caused a significant and rapid inhibit ion of the L-type 
Ca 2+ channel current (Ic~) in myocytes patch-clamped in the 
whole cell configuration (Fig. 1A). As seen in Fig. 1B, the I -V  
plot of the Ca 2+ currents recorded corresponds to that of high 
threshold L-type Ca 2+ channels, and it is clear that TNFc~ exerts 
a proport ional inhibitory action at all potentials. The I -V  plot 
does not indicate the presence of any other current components 
that might contribute to the effect on Ic, that we are attr ibuting 
to TNFct. Significantly, there was a partial recovery of the 
inward Ca 2+ current after TNFc~ washout, suggesting that a key 
second messenger may either have been removed by the wash- 
out or was turned over rapidly by the cell during that time 
period. TNF~ inhibit ion of the Ic, was dose dependent (Fig. 
1 C), displaying half-maximal inhibit ion at appproximately 6400 
U/ml. Evidence for a specific receptor-mediated mechanism for 
TNF~ action on the L-channel was suggested by neutralizing 
the inhibitory effects of TNFct with the soluble receptor frag- 
ment (sTNFRI).  In one experiment, 9000 U/ml TNFc~ inhibited 
the lc, , by 30%, while pretreatment of a cell with 4 ,ug/ml 
sTNFRI  limited the TNFc~ inhibit ion to 6.6%. sTNFRI  com- 
petes with the membrane-bound form of the native receptor to 
modulate the effects of TNF~ and has been used in other cell 
types to implicate the TNFRI  in mediating TNFc~ action [29 
31]. 
3.2. Caleium transients 
The L-type Ca 2÷ channel is an essential trigger for cardiac EC 
coupling. It has been demonstrated that Ca 2+ entry via the 
cardiac L-channel regulates the amount  of Ca 2÷ released from 
the cardiac sarcoplasmic reticulum (SR) membranes as the rate 
of SR Ca 2+ release is dependent on the peak Ic~ ~ amplitude [32]. 
Since TNF~ exhibited a significant inhibitory action on the 
cardiac L-type channel, TNF~ may interfere with the Ca 2+- 
induced Ca 2+ release (CICR) mechanism of EC coupling [33] 
by inhibiting the entry of 'trigger Ca 2+' into the cell via the 
L-channel and reducing the amount  of Ca z+ released from car- 
diac SR membranes. Accordingly, we examined actions of 
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Fig. 1. Tumor necrosis factor-or (TNF09 inhibits cardiac L-type channel Ca 2+ current. (A) L-type channel recordings from a whole cell patch- clamped 
adult rat cardiac myocyte representing one of the largest responses to TNF~ (45% inhibition of inward Ca 2÷ current (/ca)). The myocyte was treated 
for 5 min at room temperature with recombinant murine TNF~ (18,000 U/ml). There was a partial recovery after washout. Control experiments u ing 
fatty acid free BSA (data not shown) failed to show a nonspecific protein effect on the channel in the range of protein used in the TNF~ experiments. 
(B) Current-voltage r lationship for Ic, in the same cell prior to TNFc~ application (open circles), 5 min after TNFc~ application (closed circles) and 
after washout (closed triangles). (C) Average dose-dependent effect of TNF~ on L-type channel current in adult cardiac myocytes demonstrated 
half-maximal inhibition with 6400 U/ml. Holding potential -50 mV, pulses to 0 mV. 
TNFct on the Ca 2+ transients exhibited by acutely dissociated, 
electrically paced (0.3 Hz) adult rat cardiomyocytes. Fig. 2 
shows a representative c ll in which TNF~ (0.6 nM, 18,000 
U/ml) caused a progressive decrease in the amplitude of the 
Ca > transients, reaching 43% of control amplitude after 5 min. 
Of the 13 cells studied with this concentration of TNF~, the 
peak systolic indo-! ratios recorded 4-5 min after TNF~ addi- 
tion exhibited magnitudes of 46 + 24% (S.D.) of control values. 
In most of cells studied, the transients reached steady state 
levels after 5 min but sometimes took up to 15 rain. As can be 
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Fi~;. 2. Tracing showing inhibition of cardiac Ca 2+ transients by TNF0t. 
Indo 1 Ca 2+ transients of an adult rat ventricular myocyte are shown. 
Tl~ese and all subsequent Ca 2+ transient measurements were made at 
ro~m temperature from the cytoplasmic regions of individual cells 
electrically paced at 0.3 Hz. At the indicated times, 18000 U/ml recom- 
biaant murine TN F~ was added together with 10 ¢tM BSA while indo-1 
flt~orescence was continuously monitored. The [Ca2+]~ is expressed as 
th;~ ratio of indo-1 fluorescence emission at 405 and 485 nm. Control 
e~ ~eriments (not shown) established that the reduction in transients 
w, s not due to a side effect of the 10 ¢tM BSA used to prevent TNFct 
fr, m sticking to the chamber surfaces. 
seen in Fig. 2, the diastolic (resting) Ca 2+ level was not affected 
b~ TNF~. Importantly, the time course of TNF~ action on the 
peak Ca 2+ transients was similar to that exhibited by TNF~ on 
the L-type Ca 2÷ currents in that by 5 min both were significantly 
al~'ected by TNF~. Commonly, the Ca 2+ transients were more 
strongly inhibited than the L-channel Ca 2÷ currents, suggesting 
that the effect of TNF~ on L-channel Ca 2+ current only par- 
tially accounts for the inhibition of intracellular Ca 2+ release. 
O Jr data are consistent with a previous report utilizing feline 
c~rdiomyocytes [13] which demonstrated that the negative 
in otropic effect of TNF~ is exerted by an inhibition of the Ca 2+ 
tr msients and the EC coupling mechanism. Their report for 
feiine cardiac cells utilizing 200 U/ml human TNFct showed 
tl~at he Ca 2+ transients were reduced by TNF~ but the L-type 
C t 2+ channel currents were unaffected, suggesting that TNF~ 
e:,erts its effects downstream from the L-channel in the EC 
o,upling process. In contrast, our data with rat myocytes ug- 
g~. st that TNF~z-inhibition of the Ic~ can account for a signifi- 
c: nt proportion of the EC coupling deficit exhibited by TNFct- 
tr..'ated cardiac cells. 
3 3. TNFot receptor expression on isolated cardiac membranes 
The ability of TNF~ to inhibit Ic, and Ca 2÷ transients of 
si agle rat cardiac myocytes (Figs. 1A and 2, respectively) plus 
tt~e ability of sTNFRI to block TNF~'s effects on the L-channel 
as consistent with TNF~ exerting its negative inotropic effects 
b,  interaction with a specific membrane-bound receptor on the 
c,rdiac myocyte. Despite clear implications of a role for the 
cvtokine in cardiac function, studies examining the expression 
or" TNFcz receptors by cardiac cells are lacking. Two TNF~ 
receptors, type I (TNFRI, 60 kDa) and type II (TNFRII, 80 
kDa) have been identified [34] and are expressed in several 
n,m-muscle tissues [35-37]. Investigations of signaling path- 
~ays mediating cytotoxic effects of TNFct in non-cardiac cells 
have revealed a function for the TNFRI  [3,38-40] and that the 
major role of TNFRI I  is to recruit TNF~ for the TNFRI by 
a process termed 'ligand passing' [41]. 
Expression of the receptor protein on cardiac ell membranes 
was assessed initally by immunoblotting and ligand blotting 
methods. TNFRI  protein was identified with an anti-human 
TNFRI monoclonal antibody following transfer from a reduc- 
ing SDS-PAGE. As expected, a single 60 kDa molecular weight 
band corresponding to TNFRI  was obtained (Fig. 3A, lane 2) 
demonstrating that TNFRI  is expressed in the cardiac myocyte. 
Although greater than the predicted size of the rat TNFRI as 
determined by cDNA sequence (48 kDa) [42], the results are 
consistent with the Mr for TNFRI after glycosylation 
[28,42,43]. In contrast o rat cardiac membranes, TNFRI ex- 
pression in rat skeletal muscle membrane was low (Fig. 3A, lane 
3). The apparent differential expression between muscle types 
is intriguing and may be confirmed in future studies by compar- 
ing TNFRI and transcript levels as well as tissue responsiveness 
to TNFct. 
Cardiac membrane proteins were also electroblotted and 
processed for [t25I]TNFct binding. Fig. 3B (lane 2) shows that 
rat cardiac membranes possess aprominent [ 25I]TNF~-binding 
protein with Mr of 60 kDa. Identity of the [~25I]TNF~ binding 
protein as TNFRI was confirmed by Western blot analysis 
(Fig. 3B, lane 1) performed on the same blot used for the 
[~251]TNFct ligand blotting. The TNFc~ concentrations u ed for 
both ligand blotting and the physiological experiments (0.5-0.6 
nM) described above are similar to the Kd range (0.3 nM) for 
TNFct binding to the TNFRI [34]. Both ligand blots and im- 
munoblots how the presence of higher Mr bands on this non- 
reducing el. High molecular weight bands are commonly ob- 
served in studies characterizing TNF~ receptors [43,44] and 
may be due to the formation of disulfide-linked TNFct receptor 
aggregates between the cysteine-rich extracellular domains [28] 
which are particularly apparent under the non-reducing elec- 
trophoresis conditions used in the ['25I]TNFct binding experi- 
ments. The appearance offaint bands near 80 kDa in both lanes 
1 and 2 is likely an artifact of the non-reducing gel as described 
above since the monoclonal antibody to TNFRI exhibits no 
cross-reactivity to the type II receptor. The specificity of TNF~ 
binding was demonstrated in control experiments using 100- 
fold excess of cold TNFc~ which completely blocked [~25 I]TNF~ 
binding (Fig. 3B, lane 3). In contrast to cardiac membranes, rat 
skeletal muscle membranes do not possess appreciable vels of 
functional receptor as judged by their lack of [~25I]TNFc~ bind- 
ing (Fig. 3B, lane 4), an observation which confirms the low 
level of protein expression seen in Western blots (Fig. 3A, lane 
3). Importantly, the data in Figure 3B also indicate that within 
the limits of detection, cardiac muscle membranes express prin- 
cipally TNFRI, since TNF~ binding was weak in the 80 kDa 
range characteristic of TNFRII.  Our [~25I]TNFc~ binding meth- 
ods were capable of detecting both subtypes of the receptor if 
present in a particular tissue. For example, we observed at least 
two prominent [~2~I]TNF~ binding proteins in rat liver mem- 
branes (Fig. 3B, lane 5) with Mr values of 60 kDa and 80 kDa, 
corresponding to both TNFRI  and TNFRI I  subtypes, respec- 
tively. Liver membranes exhibited an additional TNF~-binding 
protein with an M r of 35 kDa. This protein is of a size corre- 
sponding to the extracellular f agment of the native TNFRI 
receptor (sTNFRI) which is often shed and retains its ability 
to bind [125I]TNF~ [45]. 
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Fig. 3. Expression of the TNFc~ type I receptor (TNFRI) on cardiac membranes. (A) Lane 1 is a 288 bp RT-PCR product amplified from reverse 
transcribed adult rat ventricular poly(A) + RNA [15,21]. The dideoxy sequenced (see text) 288 bp product corresponds toan extracellular portion 
of TNFRI. Lanes 2 and 3 are Western blots [25] from a reducing SDS-PAGE of rat cardiac membranes [16] probed with a monoclonal nti-human 
TNFR! IgG (anti-RI). A 60 kDa receptor (arrowhead) was identified in cardiac but not in skeletal muscle membranes. (B) Western immunoblot 
(lane 1) and [1251]TNFc~ ligand blots (lanes 2-5) from a non-reducing SDS-PAGE of rat membranes. A 60 kDa [~251]TNF~-binding protein (arrowhead) 
was identified in cardiac but not in skeletal muscle membranes. Specificity of the binding protein for TNFc~ was determined byeffective competition 
of [~25I]TNFc~ with a 100-fold excess of unlabelled TNF~ (+TNF~). Western blot analysis (lane 1) of the same piece of nitrocellulose used in lane 
2 of this non-reducing gel confirmed the 60 kDa binding protein as TNFRI. Rat liver membranes (lane 5) clearly expressed two [~25I]TNFc~-binding 
proteins with Mr of 60 kDa (arrowhead) and 80 kDa (asterisk) incontrast to the predominant 60 kDa protein in the rat heart. The minor band at 
35 kDa may correspond to the soluble TNF receptor (sTNFRI) as described in the text. 
3.4. S&gle cell RT -PCR 
We initially determined expression of the TNFRI gene in the 
rat heart by RT-PCR following total RNA extraction from 
cardiac tissue. The predicted 288 bp product was obtained (Fig. 
3A, lane 1). Sequencing [46] of the PCR product (Table 1) 
confirmed amplification of the extracellular domain of the rat 
TNFRI and demonstrated that this segment of the rat cardiac 
TNFRI shares 100% identity with the nucleotide sequence of 
the TNFRI obtained from the rat gliomal cell line [42]. These 
results provide evidence that the TNFRI gene is transcription- 
ally active in adult rat heart issue. It is not clear, however, that 
the ventricular myocytes themselves are the source of the 
TNFRI message amplified in Fig. 3A, lane 1. Although the 
heart consists primarily of ventricular myocytes, other cell 
types are present in heart issue such as fibroblasts, endothelial 
cells, neurons and infiltrating macrophages. These non-muscle 
cell types could be the source of the TNFRI message detected 
by RT-PCR shown in Fig. 3A, lane 1. We hypothesized that 
the receptor expression detected by RT-PCR was located on 
ventricular myocytes ince the negative inotropic effects of 
TNFc~ on cardiac Ca 2+ currents and transients were direct and 
rapid (Figs. 1,2). 
To confirm that the myocytes themselves expressed the re- 
ceptor, we performed single cell RT-PCR from mRNA ex- 
tracted from the cytoplasm of individual myocytes. This tech- 
nique has been successfully used to examine cell-specific gene 
expression without potential contamination of RNA from 
other cell types and without amplifying enomic DNA. [47]. 
Single cell PCR is advantageous over other methods which 
utilize whole tissue RNA to demonstrate g ne expression and 
is particularly useful when the level of the message in question 
is not abundant, as is the case for TNF~ receptors. Although 
the PCR method employed here cannot be used to accurately 
quantify differential gene expression, it can clearly indicate 
whether or not a particular gene is transcribed in the cell type 
of interest. In Fig. 4 (lane 2), a 288 bp PCR product was 
successfully amplified from a single cell, indicating that adult 
ventricular myocytes express the TNFRI. To eliminate the pos- 
sibility that a PCR product might be derived from DNA of 
degenerating cells in the culture dish, several cell-conditioned 
media samples were subjected to RT-PCR. An example of this 
important control experiment is shown in Fig. 4 (lane 3) and 
clearly shows the lack of PCR product. Typically 3-5 media 
controls were performed for each experiment in which cyto- 
plasmic ontents were aspirated. All of the media controls were 
free of any PCR product. Of the 28 cells from which we api- 
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Fg. 4. Expression of TNFRI in cardiac myocytes by single cell RT- 
PCR. Total RNA from an adult rat ventricular myocyte was reverse 
tl mscribed and the resulting cDNA then run in a PCR reaction with 
stnse and antisense primers for rat TNFRI resulting in a 288 bp product 
(l,me 2). Lane 3 is a media control in which 2 ¢tl of cell-conditioned 
media was aspirated for first strand cDNA synthesis and processed in
p,,rallel with the experimental lane (lane 2) containing cytoplasmic 
R NA. Lane 4 is a 212 bp RT-PCR product amplified using primers for 
rat atrial natriuretic factor (ANF). An 100 bp DNA ladder is shown 
ir lane 1 with the lowest band representing 100 bp DNA. PCR products 
~re visualized by agarose gel electrophoresis and ethidium bromide 
s~ iining. The figure is an inverted image of the original. 
r~ted cytoplasmic contents, we were able to successfully am- 
p ify 10 PCR products. In other control experiments, we exam- 
ived the expression of atrial natriuretic factor (ANF), a my- 
o,:yte-specific gene. Using rat ANF primers (see section 2), we 
egserved a characteristic 212 bp ANF gene product (Fig. 4, 
k~ne 4). 
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The presence of the TNFRI  message detected by single cell 
PCR is in agreement with Fig. 3B (lane 2) in which we identified 
an [125I]TNF~ binding protein in rat cardiac membranes with 
an Mr consistent with the TNFRI (60 kDa). 
4. Conclusions 
These experiments provide the first direct evidence for the 
presence of TNF~ receptors on rat cardiac myocyte mem- 
branes. Expression of the 60 kDa TNFRI and the receptor- 
mediated blockage of the cardiac L-channel and intracellular 
Ca 2+ transients uggest hat the negative inotropic effects of 
TNFc~ may be mediated by the TNFRI. The TNF~-mediated 
inhibition of cardiac Ca 2+ fluxes likely accounts for the depres- 
sant actions of TNFc~ on cardiac contractility by adversely 
affecting cardiac EC coupling. Since the cardiotoxic effects of 
TNF~ have limited its usefulness as a potent anti-neoplastic 
agent, and since several clinical conditions, including sepsis and 
ischemia, are complicated by TNF~'s cardiodepressant effects, 
an understanding of TNFc(s receptor-mediated signaling path- 
way(s) may be important in mitigating the cytokine's adverse 
effects. Signaling pathways coupled to TNFRI in non-muscle 
cells include cascades involving the sphingomyelinase system 
[48], phosphatidylcholine-specific phospholipase C [39], phos- 
pholipase A2 [49], nitric oxide synthase [5% and their respective 
second messengers. We are currently investigating the partici- 
pation of these pathways in mediating responses to the cardiac 
TNFRI. 
5. Note  of added proof 
Since this manuscript was submitted, a paper appeared which 
demonstrates that the TNFRI (and not the TNFRII)  is the 
principal receptor that mediates the inhibitory effects of TNF~ 
on cat myocyte cell shortening parameters [51]. This finding 
compliments our present work in which we have identified the 
source of the EC-coupling deficits caused by TNF0~. In the 
Torre-Amione t al. report, immunocytochemical staining of 
~1 tble 1 
S,~quence of rat cardiac myocyte TNFRI 
Sense  Pr imer  
[{at gliomal: GC TCCTGGCTCT GCTGATGGGG ATACACCCAT CAGGGGTCAC CGGACTGGTT 
}tat cardiac: GC TCCTGGCTCT GCTGATGGGG ATACACCCAT CAGGGGTCAC CGGACTGGTT 
(liomal: CCTTCTCTTG GTGACCGGGA GAAGAGGGAT AATTTGTGTC CCCAGGGAAA 
(ardiac: CCTTCTCTTG GTGACCGGGA GAAGAGGGAT AATTTGTGTC CCCAGGGAAA 
( liomal: GTATGCCCAT CCAAAGAATA ATTCCATCTG CTGCACCAAG TGCCACAAAG 
(ardiac: GTATGCCCAT CCAAAGAATA ATTCCATCTG CTGCACCAAG TGCCACAAAG 
(liomal: GAACCTACTT GGTGAGTGAC TGTCCAAGCC CAGGGCAGGA AACAGTCTGC 
( ardiac: GAACCTACTT GGTGAGTGAC TGTCCAAGCC CAGGGCAGGA AACAGTCTGC 
(,liomal: GAGGTGTGTG ATAAAGGCAC CTTTACAGCT TCGCAGAACC ACGTCAGACA 
(ardiac: GAGGTGTGTG ATAAAGGCAC CTTTACAGCT TCGCAGAACC ACGTCAGACA 
(,liomal: GTGTCTCAGT TGCAAGACAT GTCGGAAAGA AATGTT 
( ardiac: GTGTCTCAGT TGCAAGACAT GTCGGAAAGA AATGTT 
Ant i sense  pr imer  
qhe288 bp PCR product from theextracellulardomain ofthe TNFRIinratcardiac membranes wasl00% identicaltothe TNFRIextracellular 
domain sequence identified in rat gliomal cells. 
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human cardiac tissue suggested a myocyte localization of the 
TNFRI ,  and Northern blot analysis of human cardiac tissue 
showed the presence of the TNFRI  transcript. However, since 
the Northern blot would have included RNA from non-my- 
ocytes as well as from myocytes in the cardiac tissue, it is not 
certain that the TNFRI  came from ventricular myocytes. On 
the other hand, our single cell RT-PCR data (Fig. 4) unequiv- 
ocally localize the TNFRI  transcript to rat cardiac myocytes. 
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